<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T02:28:18Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:7527160" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:7527160</identifier>
        <datestamp>2021-10-10</datestamp>
        <setSpec>jco</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" article-type="research-article">
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">J Clin Oncol</journal-id>
              <journal-id journal-id-type="iso-abbrev">J. Clin. Oncol</journal-id>
              <journal-id journal-id-type="hwp">jco</journal-id>
              <journal-id journal-id-type="pmc">jco</journal-id>
              <journal-id journal-id-type="publisher-id">JCO</journal-id>
              <journal-title-group>
                <journal-title>Journal of Clinical Oncology</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">0732-183X</issn>
              <issn pub-type="epub">1527-7755</issn>
              <publisher>
                <publisher-name>American Society of Clinical Oncology</publisher-name>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC7527160</article-id>
              <article-id pub-id-type="pmcid">PMC7527160</article-id>
              <article-id pub-id-type="pmc-uid">7527160</article-id>
              <article-id pub-id-type="pmid">32530764</article-id>
              <article-id pub-id-type="publisher-id">1903327</article-id>
              <article-id pub-id-type="doi">10.1200/JCO.19.03327</article-id>
              <article-categories>
                <subj-group subj-group-type="subjects">
                  <compound-subject>
                    <compound-subject-part content-type="code">[NEUR]</compound-subject-part>
                    <compound-subject-part content-type="label">NEUROONCOLOGY: CNS MALIGNANCY</compound-subject-part>
                  </compound-subject>
                  <compound-subject>
                    <compound-subject-part content-type="code">[NEUR1]</compound-subject-part>
                    <compound-subject-part content-type="label">Brain Tumors</compound-subject-part>
                  </compound-subject>
                  <compound-subject>
                    <compound-subject-part content-type="code">[NEUR11]</compound-subject-part>
                    <compound-subject-part content-type="label">Targeted Therapy</compound-subject-part>
                  </compound-subject>
                  <compound-subject>
                    <compound-subject-part content-type="code">[NEUR8]</compound-subject-part>
                    <compound-subject-part content-type="label">Translational Oncology</compound-subject-part>
                  </compound-subject>
                  <compound-subject>
                    <compound-subject-part content-type="code">[FAZE]</compound-subject-part>
                    <compound-subject-part content-type="label">PHASE I AND CLINICAL PHARMACOLOGY</compound-subject-part>
                  </compound-subject>
                  <compound-subject>
                    <compound-subject-part content-type="code">[TO]</compound-subject-part>
                    <compound-subject-part content-type="label">TRANSLATIONAL ONCOLOGY</compound-subject-part>
                  </compound-subject>
                  <compound-subject>
                    <compound-subject-part content-type="code">[TO9]</compound-subject-part>
                    <compound-subject-part content-type="label">Translational Oncology: Phase I and Clinical Pharmacology</compound-subject-part>
                  </compound-subject>
                  <compound-subject>
                    <compound-subject-part content-type="code">[TO11]</compound-subject-part>
                    <compound-subject-part content-type="label">Translational Oncology: Signal Transduction</compound-subject-part>
                  </compound-subject>
                  <compound-subject>
                    <compound-subject-part content-type="code">[TIMG]</compound-subject-part>
                    <compound-subject-part content-type="label">TUMOR IMAGING</compound-subject-part>
                  </compound-subject>
                  <compound-subject>
                    <compound-subject-part content-type="code">[TIMG4]</compound-subject-part>
                    <compound-subject-part content-type="label">Tumor Imaging: MRI</compound-subject-part>
                  </compound-subject>
                </subj-group>
                <subj-group subj-group-type="heading">
                  <subject>Original Reports</subject>
                  <subj-group>
                    <subject>Neurooncology</subject>
                  </subj-group>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Ivosidenib in Isocitrate Dehydrogenase 1<italic>–</italic>Mutated Advanced Glioma</article-title>
                <alt-title alt-title-type="short">Ivosidenib in Glioma</alt-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <name>
                    <surname>Mellinghoff</surname>
                    <given-names>Ingo K.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref ref-type="aff" rid="aff1">
                    <sup>1</sup>
                  </xref>
                  <xref ref-type="corresp" rid="cor1"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Ellingson</surname>
                    <given-names>Benjamin M.</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref ref-type="aff" rid="aff2">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Touat</surname>
                    <given-names>Mehdi</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref ref-type="aff" rid="aff3">
                    <sup>3</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Maher</surname>
                    <given-names>Elizabeth</given-names>
                  </name>
                  <degrees>MD, PhD</degrees>
                  <xref ref-type="aff" rid="aff4">
                    <sup>4</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>De La Fuente</surname>
                    <given-names>Macarena I.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref ref-type="aff" rid="aff5">
                    <sup>5</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Holdhoff</surname>
                    <given-names>Matthias</given-names>
                  </name>
                  <degrees>MD, PhD</degrees>
                  <xref ref-type="aff" rid="aff6">
                    <sup>6</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Cote</surname>
                    <given-names>Gregory M.</given-names>
                  </name>
                  <degrees>MD, PhD</degrees>
                  <xref ref-type="aff" rid="aff7">
                    <sup>7</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Burris</surname>
                    <given-names>Howard</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref ref-type="aff" rid="aff8">
                    <sup>8</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Janku</surname>
                    <given-names>Filip</given-names>
                  </name>
                  <degrees>MD, PhD</degrees>
                  <xref ref-type="aff" rid="aff9">
                    <sup>9</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Young</surname>
                    <given-names>Robert J.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref ref-type="aff" rid="aff10">
                    <sup>10</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Huang</surname>
                    <given-names>Raymond</given-names>
                  </name>
                  <degrees>MD, PhD</degrees>
                  <xref ref-type="aff" rid="aff11">
                    <sup>11</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Jiang</surname>
                    <given-names>Liewen</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref ref-type="aff" rid="aff12">
                    <sup>12</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Choe</surname>
                    <given-names>Sung</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref ref-type="aff" rid="aff13">
                    <sup>13</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Fan</surname>
                    <given-names>Bin</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref ref-type="aff" rid="aff14">
                    <sup>14</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Yen</surname>
                    <given-names>Katharine</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref ref-type="aff" rid="aff15">
                    <sup>15</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Lu</surname>
                    <given-names>Min</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref ref-type="aff" rid="aff15">
                    <sup>15</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Bowden</surname>
                    <given-names>Chris</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref ref-type="aff" rid="aff16">
                    <sup>16</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Steelman</surname>
                    <given-names>Lori</given-names>
                  </name>
                  <degrees>MS</degrees>
                  <xref ref-type="aff" rid="aff16">
                    <sup>16</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Pandya</surname>
                    <given-names>Shuchi S.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref ref-type="aff" rid="aff16">
                    <sup>16</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Cloughesy</surname>
                    <given-names>Timothy F.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref ref-type="aff" rid="aff17">
                    <sup>17</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Wen</surname>
                    <given-names>Patrick Y.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref ref-type="aff" rid="aff18">
                    <sup>18</sup>
                  </xref>
                </contrib>
                <aff id="aff1"><label><sup>1</sup></label>Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY</aff>
                <aff id="aff2"><label><sup>2</sup></label>UCLA Brain Tumor Imaging Laboratory, Department of Radiological Sciences, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA</aff>
                <aff id="aff3"><label><sup>3</sup></label>Drug Development Department, Gustave Roussy Cancer Center, Villejuif, France</aff>
                <aff id="aff4"><label><sup>4</sup></label>Department of Neurology and Neurotherapeutics, University of Texas Southwestern Medical Center, Dallas, TX</aff>
                <aff id="aff5"><label><sup>5</sup></label>Department of Neurology and Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL</aff>
                <aff id="aff6"><label><sup>6</sup></label>The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD</aff>
                <aff id="aff7"><label><sup>7</sup></label>Henri and Belinda Termeer Center for Targeted Therapies, Massachusetts General Hospital Cancer Center, Boston, MA</aff>
                <aff id="aff8"><label><sup>8</sup></label>Sarah Cannon Research Institute, Nashville, TN</aff>
                <aff id="aff9"><label><sup>9</sup></label>Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX</aff>
                <aff id="aff10"><label><sup>10</sup></label>Radiology, Neuroradiology Service, Memorial Sloan Kettering Cancer Center, New York, NY</aff>
                <aff id="aff11"><label><sup>11</sup></label>Department of Radiology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Boston, MA</aff>
                <aff id="aff12"><label><sup>12</sup></label>Biostatistics, Agios Pharmaceuticals, Cambridge, MA</aff>
                <aff id="aff13"><label><sup>13</sup></label>Bioinformatics, Agios Pharmaceuticals, Cambridge, MA</aff>
                <aff id="aff14"><label><sup>14</sup></label>Pharmacology, Agios Pharmaceuticals, Cambridge, MA</aff>
                <aff id="aff15"><label><sup>15</sup></label>Clinical Sciences, Agios Pharmaceuticals, Cambridge, MA</aff>
                <aff id="aff16"><label><sup>16</sup></label>Medical, Agios Pharmaceuticals, Cambridge, MA</aff>
                <aff id="aff17"><label><sup>17</sup></label>Department of Neurology, Ronald Reagan UCLA Medical Center, University of California, Los Angeles, Los Angeles, CA</aff>
                <aff id="aff18"><label><sup>18</sup></label>Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA</aff>
              </contrib-group>
              <author-notes>
                <corresp id="cor1">Ingo K. Mellinghoff, MD, Department of Neurology and Human Oncology &amp; Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065; e-mail: <email>mellingI@mskcc.org</email>.</corresp>
                <fn id="afn1" fn-type="equal" specific-use="equal">
                  <p>I.K.M., B.M.E., and T.F.C. contributed equally to this work.</p>
                </fn>
              </author-notes>
              <pub-date pub-type="ppub">
                <day>10</day>
                <month>10</month>
                <year>2020</year>
              </pub-date>
              <pub-date pub-type="epub">
                <day>12</day>
                <month>6</month>
                <year>2020</year>
              </pub-date>
              <pub-date pub-type="pmc-release">
                <day>10</day>
                <month>10</month>
                <year>2021</year>
              </pub-date>
              <!-- PMC Release delay is 12 months and
						0 days and was based on the <pub-date
						pub-type="ppub"/>. -->
              <volume>38</volume>
              <issue>29</issue>
              <fpage>3398</fpage>
              <lpage>3406</lpage>
              <history>
                <date date-type="accepted">
                  <day>10</day>
                  <month>4</month>
                  <year>2020</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>© 2020 by American Society of Clinical Oncology</copyright-statement>
                <copyright-year>2020</copyright-year>
                <copyright-holder>American Society of Clinical Oncology</copyright-holder>
                <license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
                  <license-p>Creative Commons Attribution Non-Commercial No Derivatives 4.0 License: <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">https://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link></license-p>
                </license>
              </permissions>
              <self-uri content-type="pdf" xlink:title="pdf" xlink:href="JCO.19.03327.pdf"/>
              <abstract>
                <sec>
                  <title>PURPOSE</title>
                  <p>Diffuse gliomas are malignant brain tumors that include lower-grade gliomas (LGGs) and glioblastomas. Transformation of low-grade glioma into a higher tumor grade is typically associated with contrast enhancement on magnetic resonance imaging. Mutations in the isocitrate dehydrogenase 1 (<italic>IDH1</italic>) gene occur in most LGGs (&gt; 70%). Ivosidenib is an inhibitor of mutant IDH1 (mIDH1) under evaluation in patients with solid tumors.</p>
                </sec>
                <sec>
                  <title>METHODS</title>
                  <p>We conducted a multicenter, open-label, phase I, dose escalation and expansion study of ivosidenib in patients with m<italic>IDH1</italic> solid tumors. Ivosidenib was administered orally daily in 28-day cycles.</p>
                </sec>
                <sec>
                  <title>RESULTS</title>
                  <p>In 66 patients with advanced gliomas, ivosidenib was well tolerated, with no dose-limiting toxicities reported. The maximum tolerated dose was not reached; 500 mg once per day was selected for the expansion cohort. The grade ≥ 3 adverse event rate was 19.7%; 3% (n = 2) were considered treatment related. In patients with nonenhancing glioma (n = 35), the objective response rate was 2.9%, with 1 partial response. Thirty of 35 patients (85.7%) with nonenhancing glioma achieved stable disease compared with 14 of 31 (45.2%) with enhancing glioma. Median progression-free survival was 13.6 months (95% CI, 9.2 to 33.2 months) and 1.4 months (95% CI, 1.0 to 1.9 months) for the nonenhancing and enhancing glioma cohorts, respectively. In an exploratory analysis, ivosidenib reduced the volume and growth rates of nonenhancing tumors.</p>
                </sec>
                <sec>
                  <title>CONCLUSION</title>
                  <p>In patients with m<italic>IDH1</italic> advanced glioma, ivosidenib 500 mg once per day was associated with a favorable safety profile, prolonged disease control, and reduced growth of nonenhancing tumors.</p>
                </sec>
              </abstract>
              <counts>
                <fig-count count="2"/>
                <table-count count="3"/>
                <equation-count count="0"/>
                <ref-count count="45"/>
                <page-count count="11"/>
              </counts>
              <custom-meta-group>
                <custom-meta>
                  <meta-name> SJS Export </meta-name>
                  <meta-value>v1</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
          </front>
          <body>
            <sec sec-type="intro" id="s1">
              <title>INTRODUCTION</title>
              <p>Diffuse gliomas represent the most common malignant primary brain tumor in adults and include glioblastoma (GBM) and WHO grade 2 and WHO grade 3 tumors. The latter are referred to as lower-grade gliomas (LGGs). LGGs grow at a slower rate, but eventually “transform” into a higher tumor grade.<sup><xref rid="B1" ref-type="bibr">1</xref></sup> Patients with LGGs with long-term disease control suffer from treatment-related symptoms, including radiation-induced cognitive changes.<sup><xref rid="B2" ref-type="bibr">2</xref>-<xref rid="B5" ref-type="bibr">5</xref></sup> Brain magnetic resonance imaging (MRI) plays a central role in disease monitoring.<sup><xref rid="B6" ref-type="bibr">6</xref>,<xref rid="B7" ref-type="bibr">7</xref></sup> Malignant transformation of LGGs is often associated with the appearance of contrast enhancement.</p>
              <boxed-text id="b1" position="anchor" orientation="portrait">
                <sec>
                  <title>CONTEXT</title>
                  <p>
                    <list list-type="simple" id="L1">
                      <list-item>
                        <p>
                          <bold>Key Objectives</bold>
                        </p>
                      </list-item>
                      <list-item>
                        <p>To determine safety and tolerability of oral ivosidenib as a single agent in patients with glioma and to determine the recommended phase II dose.</p>
                      </list-item>
                      <list-item>
                        <p>
                          <bold>Knowledge Generated</bold>
                        </p>
                      </list-item>
                      <list-item>
                        <p>Ivosidenib was well tolerated, with no dose-limiting toxicities. 500 mg once per day was selected for the expansion cohort. In exploratory analyses, ivosidenib reduced the growth of nonenhancing tumors.</p>
                      </list-item>
                      <list-item>
                        <p>
                          <bold>Relevance</bold>
                        </p>
                      </list-item>
                      <list-item>
                        <p>Our findings point toward an important contribution of the mutant IDH1 enzyme to the growth of m<italic>IDH1</italic> LGGs. Further evaluation of mIDH inhibitors for the treatment of m<italic>IDH</italic> LGGs appears warranted.</p>
                      </list-item>
                    </list>
                  </p>
                </sec>
              </boxed-text>
              <p>Mutations in the isocitrate dehydrogenase 1 (<italic>IDH1</italic>) gene, and less commonly in the <italic>IDH2</italic> gene, are found in more than 70% of LGGs.<sup><xref rid="B8" ref-type="bibr">8</xref></sup>
<italic>IDH</italic> mutant (m<italic>IDH</italic>) gliomas have emerged as a separate glioma entity with a distinct molecular pathogenesis. <italic>IDH</italic> mutations in glioma occur early during tumor development, cluster in key arginine residues within the enzyme’s active site, are associated with a distinctive pattern of DNA hypermethylation, persist throughout the disease, and are associated with a better prognosis compared with <italic>IDH</italic> wildtype gliomas of the same tumor grade.<sup><xref rid="B8" ref-type="bibr">8</xref>-<xref rid="B15" ref-type="bibr">15</xref></sup> Cancer-associated <italic>IDH1</italic>/<italic>2</italic> mutations lead to the abnormal production of the oncometabolite D(-)-2-hydroxyglutarate (2-HG),<sup><xref rid="B16" ref-type="bibr">16</xref>,<xref rid="B17" ref-type="bibr">17</xref></sup> which inhibits α-ketoglutarate–dependent enzymes, resulting in tumorigenesis.<sup><xref rid="B18" ref-type="bibr">18</xref>-<xref rid="B20" ref-type="bibr">20</xref></sup></p>
              <p>The contribution of mIDH enzymes to the growth of established cancers remains incompletely understood. Inhibition of the mIDH enzyme reduced tumor cell proliferation in experimental models of m<italic>IDH</italic> leukemia and m<italic>IDH</italic> glioma.<sup><xref rid="B21" ref-type="bibr">21</xref>,<xref rid="B22" ref-type="bibr">22</xref></sup> In clinical trials for patients with advanced acute myeloid leukemia, another human cancer harboring <italic>IDH</italic> mutations,<sup><xref rid="B23" ref-type="bibr">23</xref>,<xref rid="B24" ref-type="bibr">24</xref></sup> the first-in-class, Food and Drug Administration–approved inhibitors of mIDH2 (enasidenib) and mIDH1 (ivosidenib) induced clinical and molecular remissions.<sup><xref rid="B25" ref-type="bibr">25</xref>,<xref rid="B26" ref-type="bibr">26</xref></sup></p>
              <p>We designed a multicenter, open-label, phase I dose escalation and expansion study of ivosidenib in patients with m<italic>IDH1</italic> advanced solid tumors. Data from cholangiocarcinoma and chondrosarcoma cohorts have been reported.<sup><xref rid="B27" ref-type="bibr">27</xref>,<xref rid="B28" ref-type="bibr">28</xref></sup> Here we report results for the advanced glioma cohort in the phase I study, including LGG and GBM.</p>
            </sec>
            <sec sec-type="methods" id="s2">
              <title>METHODS</title>
              <sec id="s3">
                <title>Study Design</title>
                <p>This phase I, multicenter, open-label study comprised a dose escalation and a dose expansion phase (Data Supplement, online only). The primary objectives were to assess the safety and tolerability of oral ivosidenib as a single agent and to determine the maximum tolerated dose or recommended phase II dose of ivosidenib in patients with solid tumors. Secondary objectives included evaluation of dose-limiting toxicities (DLTs) during cycle 1 of dose escalation, pharmacokinetic and pharmacodynamic findings (reported elsewhere<sup><xref rid="B29" ref-type="bibr">29</xref></sup>), and characterization of preliminary clinical response. DLTs were defined as any grade ≥ 3 event reported to be at least possibly related to ivosidenib. The data reported here are from patients with glioma who were enrolled in both phases.</p>
                <p>Patients underwent baseline screening evaluations within 28 days before study day 1. Dose escalation was performed using a 3+3 design, with patients enrolled into sequential 3-patient cohorts of increasing doses from 100 mg twice per day (200 mg/d) to 1,200 mg once per day. Treatment with ivosidenib was continuous; 1 cycle was defined as 28 days.</p>
              </sec>
              <sec id="s4">
                <title>Patients</title>
                <p>Eligible patients included men and women ≥ 18 years of age with an Eastern Cooperative Oncology Group performance status of 0 to 1 and an expected survival of ≥ 3 months. All patients had an established diagnosis of m<italic>IDH1</italic> glioma that had recurred after, or not responded to, initial surgery, radiation, or chemotherapy. <italic>IDH1</italic> mutation status was based on local laboratory testing with retrospective central confirmation. Because this study was initiated before the most recent revision of the WHO Classification of Tumors of the Central Nervous System,<sup><xref rid="B30" ref-type="bibr">30</xref></sup> we used the 2007 classification.<sup><xref rid="B31" ref-type="bibr">31</xref></sup></p>
                <p>Transformation of LGGs to a higher tumor grade is frequently associated with the appearance of tumor contrast enhancement on T1-weighted brain MRI. For the dose expansion phase, patients were therefore separated into 2 cohorts on the basis of the presence or absence of tumor contrast enhancement at the time of enrollment according to the investigator. The “nonenhancing” glioma cohort comprised patients with m<italic>IDH1</italic> glioma that had progressed within 12 months before enrollment and did not enhance on T1-weighted postgadolinium MRI. Patients in this cohort required at least 3 full sets of “historical” MRI examinations (not including screening), each separated by at least 2 months, and were ineligible if they had had surgery or radiation therapy within 6 months of enrollment. The second cohort comprised patients with progressive m<italic>IDH1</italic> gliomas who did not meet these criteria.</p>
              </sec>
              <sec id="s5">
                <title>Study Oversight</title>
                <p>The study was designed by the sponsor in collaboration with the lead investigators. Clinical data were generated by investigators and research staff at each participating site. Safety data were reviewed at regular intervals by study investigators and the sponsor. All authors vouch for the accuracy and completeness of the data and analyses and for the adherence of the study to the protocol. The study was conducted in accordance with the principles of the Declaration of Helsinki and Good Clinical Practice guidelines. The protocol was approved by relevant institutional review boards or ethics committees at each site. Written informed consent was provided by all the patients before screening and enrollment.</p>
              </sec>
              <sec id="s6">
                <title>Study Assessments</title>
                <p>Toxicity was evaluated by the collection of adverse events (AEs), serious AEs, and AEs leading to discontinuation, graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events v4.03. Treatment efficacy was assessed by investigators using MRI every 2 cycles (56 ± 3 days) according to Response Assessment in Neuro-Oncology (RANO) criteria for high-grade gliomas<sup><xref rid="B32" ref-type="bibr">32</xref></sup> for all patients in the dose escalation phase and for those with enhancing glioma in the expansion phase. For patients with nonenhancing glioma in the expansion cohort, response was assessed using the RANO criteria for LGG (RANO LGG).<sup><xref rid="B33" ref-type="bibr">33</xref></sup> End points included best overall response and objective response rate (defined as complete response plus partial response plus minor response). Progression-free survival (PFS) was defined as the interval from first dose to disease progression or death.</p>
              </sec>
              <sec id="s7">
                <title>Exploratory Assessments</title>
                <p>Tumor growth rate was assessed by volume in the nonenhancing glioma expansion cohort. Tumor volume measurements were performed at the same visits as the RANO assessments using either 2-dimensional T2-weighted images, 3-dimensional T2-weighted images, or fluid-attenuated inversion recovery (FLAIR) images in compliance with the international standardized brain tumor imaging protocol.<sup><xref rid="B34" ref-type="bibr">34</xref></sup> All patients needed at least 3 “historical” pretreatment MRIs, each separated by ≥ 2 months, acquired with ≤ 5-mm slice thickness and up to 1-mm interslice gap. Tumor volumes were segmented using a semiautomated approach by an imaging contract research organization (MedQIA, Los Angeles, CA). A centralized review of coregistered MRIs was also performed. In a post hoc exploratory analysis, the tumor growth rate after treatment versus before treatment was determined using a linear mixed-effects model.<sup><xref rid="B35" ref-type="bibr">35</xref></sup> Using this model, the percentage change in tumor volume per 6 months was derived from the slope estimates from the mixed-effects model, adjusted for 6 months.</p>
                <p>Exploratory assessments also included confirmation of baseline m<italic>IDH1</italic> status and identification of co-occurring mutations. Archival formalin-fixed paraffin-embedded samples were collected for analysis by next-generation sequencing using the FoundationOne panel (Foundation Medicine, Cambridge, MA),<sup><xref rid="B36" ref-type="bibr">36</xref></sup> which includes 361 genes. Foundation Medicine provides a “known/likely oncogenic” call to identify known or likely oncogenic variants on the basis of current literature and likely somatic status of the variant.</p>
              </sec>
              <sec id="s8">
                <title>Statistical Analysis</title>
                <p>The safety analysis set comprised all patients with glioma who received at least 1 dose of study treatment. Patients who had received at least 1 dose of ivosidenib were included in the efficacy analysis. Efficacy results are reported separately for contrast-enhancing and nonenhancing tumors, and they combine the dose escalation and dose expansion cohorts. Descriptive statistics are reported for safety outcomes and other clinical parameters. PFS was estimated using Kaplan-Meier methods, and medians with associated 95% CIs were calculated. Statistical analyses were carried out (by L.J.) using SAS software version 9.3 or higher. Association of baseline gene or pathway mutation status and PFS was assessed using the log-rank test.</p>
              </sec>
            </sec>
            <sec sec-type="results" id="s9">
              <title>RESULTS</title>
              <sec id="s10">
                <title>Patients</title>
                <p>This study was initiated in March 2014 across 12 study sites in the United States and one in France, and 168 patients with m<italic>IDH1</italic> solid tumors were enrolled, including 66 with glioma. At the data cutoff date (January 16, 2019), enrollment was complete, and the study was ongoing. Twelve of 66 patients (18.2%) had GBM; the remainder had LGGs. The median number of prior systemic therapies was 2 (range, 1 to 6) and included temozolomide (48 of 66 patients); combination procarbazine, lomustine, and vincristine (eight of 66 patients); and bevacizumab (10 of 66 patients). Forty-nine of 66 patients had received prior radiotherapy (<xref rid="T1" ref-type="table">Table 1</xref>).</p>
                <table-wrap id="T1" orientation="portrait" position="float">
                  <label>TABLE 1.</label>
                  <caption>
                    <p>Baseline Characteristics of All Patients With Glioma</p>
                  </caption>
                  <graphic xlink:href="JCO.19.03327t1"/>
                </table-wrap>
                <p>Twenty patients were treated in the dose escalation phase, and 46 were treated in the dose expansion phase (24 with nonenhancing disease). In the dose escalation phase, patients received ivosidenib doses of 100 mg twice per day (n = 1), 300 mg once per day (n = 6), 500 mg once per day (n = 4), 600 mg once per day (n = 5), and 900 mg once per day (n = 4). Fifty patients received 500 mg once per day (4 in dose escalation and all 46 patients in dose expansion). At the data cutoff date, 15 patients (22.7%) were still receiving treatment and 51 (77.3%) had discontinued; all but one discontinued for disease progression (Data Supplement).</p>
              </sec>
              <sec id="s11">
                <title>Safety</title>
                <p>No DLTs were reported, and the maximum tolerated dose was not reached. A dose of 500 mg once per day was selected for expansion on the basis of the pharmacokinetic/pharmacodynamic data from all solid tumor cohorts, including less-than-dose-proportional increases in exposure and maximum suppression of plasma 2-HG at 500 mg in patients with nonglioma solid tumors, as well as the safety profile and preliminary clinical activity observed in the dose escalation phase. Plasma 2-HG was not elevated above normal levels in patients with glioma.<sup><xref rid="B29" ref-type="bibr">29</xref></sup></p>
                <p>Most patients (63 of 66 [95.5%]) experienced at least 1 AE of any grade or causality. The most common AEs (≥ 10%) were headache (39.4%), nausea (22.7%), fatigue (22.7%), vomiting (19.7%), seizure (18.2%), diarrhea (16.7%), hyperglycemia (15.2%), aphasia (15.2%), neutrophil count decreased (12.1%), depression (10.6%), hypophosphatemia (10.6%), and paresthesia (10.6%; <xref rid="T2" ref-type="table">Table 2</xref>; Data Supplement). Grade ≥ 3 AEs were observed in 13 of 66 patients (19.7%). These included headache (4.5%), hypophosphatemia (3.0%), and seizure (3.0%; <xref rid="T2" ref-type="table">Table 2</xref>; Data Supplement). Treatment-related AEs were observed in 39 of 66 patients (59.1%); most were grade 1 or grade 2. The most common treatment-related AEs of any grade were fatigue (13.6%), decreased neutrophil count (12.1%), and diarrhea (10.6%; Data Supplement). Grade ≥ 3 treatment-related AEs were reported in 2 patients (neutropenia, decreased weight, hyponatremia, and arthralgia). Serious AEs were reported for 11 patients (16.7%), but none were considered related to treatment. No patients discontinued study treatment owing to an AE. Eight patients (12.1%) had a dose interruption because of an AE; no patients required dose reduction for AEs. Two patients (3.0%) died within 30 days of the last dose (unrelated to AEs; both had enhancing glioma and both had received ivosidenib 500 mg once per day). There were no clinically meaningful changes in hematology parameters, coagulation parameters, vital signs, physical examination assessments, left ventricular ejection fraction, or Eastern Cooperative Oncology Group performance status.</p>
                <table-wrap id="T2" orientation="portrait" position="float">
                  <label>TABLE 2.</label>
                  <caption>
                    <p>Adverse Events Occurring in ≥ 10% of Patients With Glioma</p>
                  </caption>
                  <graphic xlink:href="JCO.19.03327t2"/>
                </table-wrap>
              </sec>
              <sec id="s12">
                <title>Investigator-Reported Response</title>
                <p>All 66 patients in the dose escalation and dose expansion phases were evaluable for efficacy. According to the investigator’s assessment of response, 1 patient had a partial response, 44 patients (66.7%) had a best response of stable disease, and 21 patients (31.8%) had a best response of progressive disease.</p>
                <p>As of the data cutoff, patients with nonenhancing tumors had a median treatment duration of 18.4 months (range, 1.4-47.2 months) compared with a treatment duration of 1.9 months (range, 0.4-39.9 months) for patients with enhancing tumors. Fifteen (22.7%) remained on treatment (<xref ref-type="fig" rid="f1">Figs 1A and 1B</xref>). In patients with measurable disease at baseline, tumor measurements decreased from baseline in 22 of 33 nonenhancing tumors (66.7%) and in 9 of 27 enhancing tumors (33.3%; <xref ref-type="fig" rid="f1">Fig 1C</xref>). The patient with a partial response had a nonenhancing tumor and received ivosidenib 500 mg once per day. The majority of patients had disease control, with a best response of stable disease observed in 30 of 35 patients with nonenhancing tumors (85.7%) and 14 of 31 patients with enhancing tumors (45.2%; <xref rid="T3" ref-type="table">Table 3</xref>). The median PFS times were 13.6 months (95% CI, 9.2 to 33.2 months) and 1.4 months (95% CI, 1.0 to 1.9 months) for the nonenhancing and enhancing glioma cohorts, respectively, across all doses (<xref ref-type="fig" rid="f1">Fig 1D</xref>). PFS curves for patients receiving 500 mg were similar (Data Supplement).</p>
                <fig id="f1" fig-type="figure" orientation="portrait" position="float">
                  <label>FIG 1.</label>
                  <caption>
                    <p>Clinical activity and efficacy of ivosidenib in patients with glioma. (A) Time receiving ivosidenib for the 35 patients with nonenhancing glioma. Twelve patients remain on treatment as of the data cutoff. (B) Time receiving ivosidenib for the 31 patients with enhancing glioma. Three patients remain on treatment as of the data cutoff. (C) Best response in evaluable patients with measurable disease (27 enhancing and 33 nonenhancing), expressed as the percent change in sum of products of the diameters from the target lesions at start of treatment. (D) Investigator-assessed progression-free survival according to glioma type for all evaluable patients with glioma (n = 66). Tick marks indicate censored data. PD, progressive disease; PR, partial response; SD, stable disease. (*) Lesion growth &gt; 100%. (†) Two patients with enhancing disease had decreases of &gt; 50% that were not confirmed and are indicated as SD.</p>
                  </caption>
                  <graphic xlink:href="JCO.19.03327f1"/>
                </fig>
                <table-wrap id="T3" orientation="portrait" position="float">
                  <label>TABLE 3.</label>
                  <caption>
                    <p>Investigator-Reported Best Overall Response in Efficacy-Evaluable Patients</p>
                  </caption>
                  <graphic xlink:href="JCO.19.03327t3"/>
                </table-wrap>
              </sec>
              <sec id="s13">
                <title>Exploratory Evaluation of Tumor Genetics</title>
                <p>We examined tumor genetic profiles by targeted sequencing for 15 patients with enhancing glioma and for 16 with nonenhancing glioma. In the nonenhancing glioma group, the presence of genetic alterations in cell cycle pathway genes was associated with shorter PFS (<italic>P</italic> &lt; .001; Data Supplement).</p>
              </sec>
              <sec id="s14">
                <title>Exploratory Evaluation of Tumor Volume Growth Rates</title>
                <p>We supplemented the investigator-based assessment of tumor response with a quantitative evaluation of tumor volumes before and during treatment with ivosidenib for all 24 patients in the nonenhancing expansion cohort. As defined by the study protocol, this analysis included at least 3 brain MRIs before enrollment, each separated by at least 2 months. No patient had received surgery or radiation within 6 months before enrollment. In total, this analysis included 239 MRI scans from 24 patients, including 63 historical MRIs. The estimated tumor growth rate per 6 months was 26% (95% CI, 9% to 46%) in the pretreatment period and 9% (95% CI, 1% to 20%) with ivosidenib (Data Supplement). The percentage change of tumor growth rate after treatment versus before treatment estimated from the model was –14% (95% CI, –25% to –0.4%).</p>
                <p>We also performed a centralized review of MRIs after image coregistration to minimize scan-to-scan variability related to head tilt.<sup><xref rid="B37" ref-type="bibr">37</xref></sup>
<xref ref-type="fig" rid="f2">Figure 2</xref> and Data Supplement show brain MRIs and manually segmented tumor volume growth curves for selected patients with nonenhancing glioma. Patient 1 had an anaplastic oligodendroglioma that was initially treated with surgery, radiation, and temozolomide. Following this initial tumor therapy, the patient was off therapy for 3 years and developed a slowly progressive T2/FLAIR signal abnormality. Visual inspection of coregistered images and volume growth curves showed tumor shrinkage after the initiation of ivosidenib (<xref ref-type="fig" rid="f2">Fig 2A</xref>). Despite a best response of stable disease according to the investigator, this patient subsequently achieved partial response by RANO LGG. Patient 2 had an astrocytoma and had undergone tumor resection 6 years before enrollment and had received no additional therapy in the interim. MRIs demonstrated an increase in tumor volume before enrollment. Visual inspection of coregistered images and volume growth curves showed tumor shrinkage after initiation of ivosidenib (<xref ref-type="fig" rid="f2">Fig 2B</xref>). Best response by investigator for this patient was stable disease. Patient 3 had an oligodendroglioma diagnosed 4 years before enrollment and was observed without additional therapy since the initial surgery. Treatment with ivosidenib resulted in reduction of tumor volumes (<xref ref-type="fig" rid="f2">Fig 2C</xref>). Best response by investigator for this patient was stable disease. Patient 4 had an oligodendroglioma diagnosed by biopsy 8 years before enrollment, was initially treated with surgery and 1 year of temozolomide, and then was observed for 7 years without additional therapy. The gradual increase in tumor volume before enrollment stabilized after initiation of ivosidenib (<xref ref-type="fig" rid="f2">Fig 2D</xref>). Best response by investigator for this patient was stable disease. All of these patients were receiving ivosidenib at the time of analysis.</p>
                <fig id="f2" fig-type="figure" orientation="portrait" position="float">
                  <label>FIG 2.</label>
                  <caption>
                    <p>(A-D) Examples of brain magnetic resonance images and manually segmented tumor volume growth curves in 4 patients with nonenhancing glioma treated with ivosidenib. IVO, ivosidenib; Tx, treatment with ivosidenib.</p>
                  </caption>
                  <graphic xlink:href="JCO.19.03327f2"/>
                </fig>
              </sec>
            </sec>
            <sec sec-type="discussion" id="s15">
              <title>DISCUSSION</title>
              <p>The majority of human LGGs harbor <italic>IDH</italic> mutations.<sup><xref rid="B30" ref-type="bibr">30</xref></sup> Standard treatment of LGG consists of radiation and chemotherapy. There are no approved molecularly targeted therapies for LGG, and <italic>IDH</italic> mutations represent a novel opportunity for early therapeutic intervention. Our study shows that continuous daily oral therapy with ivosidenib was well tolerated and was not associated with DLTs in patients with advanced m<italic>IDH1</italic> glioma. An ivosidenib dose of 500 mg once per day was selected for the expansion phase.</p>
              <p>The median PFS for patients with nonenhancing gliomas in our study compares favorably to that reported for temozolomide in advanced m<italic>IDH1</italic> LGG (approximately 7 months).<sup><xref rid="B38" ref-type="bibr">38</xref></sup> However, comparisons with earlier LGG studies, and in particular retrospective single-center studies, should be made with caution because these studies often included patients with both <italic>IDH</italic> wildtype and m<italic>IDH</italic> LGGs and used variable definitions of disease progression (ie, treatment-naïve progressive disease <italic>v</italic> progression after standard therapy).<sup><xref rid="B39" ref-type="bibr">39</xref></sup> More direct evidence for the antitumor activity of ivosidenib in m<italic>IDH</italic> LGG stems from our exploratory analysis of tumor volumes, which documented shrinkage in several patients. Compared with conventional 2-dimensional measurements, tumor volume measurements that incorporate changes in tumor growth rates may represent the diffuse intracranial growth of LGG with greater confidence and accuracy,<sup><xref rid="B7" ref-type="bibr">7</xref>,<xref rid="B40" ref-type="bibr">40</xref></sup> but broader implementation of this approach for LGG will require harmonization of image acquisition and analysis,<sup><xref rid="B34" ref-type="bibr">34</xref>,<xref rid="B41" ref-type="bibr">41</xref></sup> as well as regulatory guidance.</p>
              <p>Despite the heterogeneous patient population in our trial, the nonrandomized design, and the lack of central pathology review, the data from our trial suggest that ivosidenib has greater activity against nonenhancing gliomas than against enhancing gliomas. This finding may seem surprising because the absence of contrast enhancement is typically associated with impaired drug delivery. In a perioperative clinical trial (ClinicalTrials.gov identifier: <ext-link ext-link-type="uri" xlink:href="http://www.clinicaltrials.gov/ct2/show/NCT03343197">NCT03343197</ext-link>), we recently observed that ivosidenib (at 500 mg once per day orally) reduces intratumoral 2-HG levels in nonenhancing gliomas by &gt; 90%<sup><xref rid="B42" ref-type="bibr">42</xref></sup> and is associated with objective responses. We hypothesize that ivosidenib may be more effective in nonenhancing gliomas because these tumors represent an earlier disease stage with fewer genetic alterations, reminiscent of the greater antitumor activity of the BCR-ABL inhibitor imatinib in earlier stages of chronic myeloid leukemia.<sup><xref rid="B43" ref-type="bibr">43</xref>,<xref rid="B44" ref-type="bibr">44</xref></sup> In support of this hypothesis, we found that the presence of genetic alterations in cell cycle genes (lesions that are associated with LGG progression)<sup><xref rid="B5" ref-type="bibr">5</xref>,<xref rid="B45" ref-type="bibr">45</xref></sup> was associated with shorter PFS within the subgroup of nonenhancing gliomas. On the basis of these data, additional clinical development of mIDH inhibitors for m<italic>IDH</italic> low-grade gliomas is warranted.</p>
            </sec>
          </body>
          <back>
            <fn-group content-type="supported-by">
              <title>SUPPORT</title>
              <fn specific-use="supported-by" fn-type="supported-by">
                <p>Supported by Agios Pharmaceuticals. Translational research studies were supported by National Institutes of Health Grant Nos. 1 R35 NS105109 01 and P30CA008748 (I.K.M.) and the National Brain Tumor Society Defeat GBM Initiative (I.K.M. and T.F.C.).</p>
              </fn>
            </fn-group>
            <fn-group content-type="trial">
              <title>CLINICAL TRIAL INFORMATION</title>
              <fn specific-use="trial" fn-type="trial">
                <p>
                  <ext-link ext-link-type="uri" xlink:href="http://www.clinicaltrials.gov/ct2/show/NCT02073994">NCT02073994</ext-link>
                </p>
              </fn>
            </fn-group>
            <ack>
              <title>ACKNOWLEDGMENT</title>
              <p>We thank the participating patients and their families, and the nurses, research coordinators, and study management team. Tara Nimkar of Agios Pharmaceuticals provided operational support for this study. MedQIA (Los Angeles, CA) assisted with image analysis. Medical writing support was provided by Mark Poirier of Excel Scientific Solutions, Fairfield, CT.</p>
            </ack>
            <sec id="s17">
              <title>AUTHOR CONTRIBUTIONS</title>
              <p><bold>Conception and design:</bold> Ingo K. Mellinghoff, Benjamin M. Ellingson, Mehdi Touat, Gregory M. Cote, Howard Burris, Robert J. Young, Raymond Huang, Chris Bowden, Shuchi S. Pandya, Timothy F. Cloughesy, Patrick Y. Wen</p>
              <p><bold>Provision of study material or patients</bold><bold>:</bold> Mehdi Touat, Howard Burris, Filip Janku, Timothy F. Cloughesy, Patrick Y. Wen</p>
              <p><bold>Collection and assembly of data:</bold> Ingo K. Mellinghoff, Benjamin M. Ellingson, Mehdi Touat, Elizabeth Maher, Macarena I. De La Fuente, Matthias Holdhoff, Howard Burris, Filip Janku, Robert J. Young, Raymond Huang, Lori Steelman, Shuchi S. Pandya, Timothy F. Cloughesy, Patrick Y. Wen</p>
              <p><bold>Data analysis and interpretation:</bold> Ingo K. Mellinghoff, Mehdi Touat, Gregory M. Cote, Howard Burris, Raymond Huang, Liewen Jiang, Sung Choe, Bin Fan, Katharine Yen, Min Lu, Chris Bowden, Lori Steelman, Shuchi S. Pandya, Timothy F. Cloughesy, Patrick Y. Wen</p>
              <p><bold>Manuscript writing:</bold> All authors</p>
              <p><bold>Final approval of manuscript:</bold> All authors</p>
              <p><bold>Accountable for all aspects of the work:</bold> All authors</p>
            </sec>
            <sec id="s18">
              <title>AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST</title>
              <sec id="s19">
                <title>Ivosidenib in Isocitrate Dehydrogenase 1<italic>–</italic>Mutated Advanced Glioma</title>
                <p>The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to <ext-link ext-link-type="uri" xlink:href="http://www.asco.org/rwc">www.asco.org/rwc</ext-link> or <ext-link ext-link-type="uri" xlink:href="http://ascopubs.org/jco/authors/author-center">ascopubs.org/jco/authors/author-center</ext-link>.</p>
                <p>Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (<ext-link ext-link-type="uri" xlink:href="https://openpaymentsdata.cms.gov/">Open Payments</ext-link>).</p>
              </sec>
              <sec id="s20">
                <title>Ingo K. Mellinghoff</title>
                <p><bold>Honoraria:</bold> Roche</p>
                <p><bold>Consulting or Advisory Role:</bold> Agios, Puma Biotechnology, Debiopharm Group, Black Diamond Therapeutics, Voyager Therapeutics</p>
                <p><bold>Research Funding:</bold> General Electric, Amgen, Lilly</p>
                <p><bold>Travel, Accommodations, Expenses:</bold> Voyager Therapeutics, AstraZeneca, Roche, Puma Biotechnology, Agios</p>
              </sec>
              <sec id="s21">
                <title>Benjamin M. Ellingson</title>
                <p><bold>Consulting or Advisory Role:</bold> Siemens, Roche/Genentech, Bristol-Myers Squibb, Northwest Biotherapeutics, Nativis, Omniox, Agios, Medicenna, MedQIA, Novogen, Tocagen, Imaging Endpoints</p>
                <p><bold>Research Funding:</bold> Siemens, Roche/Genentech, Agios</p>
                <p><bold>Travel, Accommodations, Expenses:</bold> Siemens</p>
              </sec>
              <sec id="s22">
                <title>Mehdi Touat</title>
                <p><bold>Consulting or Advisory Role:</bold> Agios, Taiho Pharmaceutical, Integragen</p>
                <p><bold>Travel, Accommodations, Expenses:</bold> Merck Sharp &amp; Dohme</p>
              </sec>
              <sec id="s23">
                <title>Elizabeth Maher</title>
                <p><bold>Consulting or Advisory Role:</bold> Agios, Curadev, Curadev (I), FORMA Therapeutics</p>
                <p><bold>Research Funding:</bold> Curadev, Curadev (I)</p>
                <p><bold>Travel, Accommodations, Expenses:</bold> Agios, FORMA Therapeutics</p>
              </sec>
              <sec id="s24">
                <title>Macarena I. De La Fuente</title>
                <p><bold>Consulting or Advisory Role:</bold> Agios, Puma Biotechnology, Foundation Medicine, FORMA Therapeutics</p>
                <p><bold>Other Relationship:</bold> Targeted Oncology (I), OncLIve (I), OncInfo (I)</p>
              </sec>
              <sec id="s25">
                <title>Matthias Holdhoff</title>
                <p><bold>Consulting or Advisory Role:</bold> Celgene, AbbVie, BTG, Newlink Genetics, DPClinical</p>
                <p><bold>Travel, Accommodations, Expenses:</bold> Arbor Pharmaceuticals</p>
              </sec>
              <sec id="s26">
                <title>Gregory M. Cote</title>
                <p><bold>Consulting or Advisory Role:</bold> Agios, PharmaMar, Epizyme</p>
                <p><bold>Research Funding:</bold> Macrogenics (Inst), Boston Biomedical (Inst), PharmaMar (Inst), Epizyme (Inst), Agios (Inst), Eisai (Inst), Merck (Inst), Plexxikon (Inst), CBA (Inst), Bavarian Nordic</p>
                <p><bold>Research Funding:</bold> Bayer (Inst), Springworks Therapeutics (Inst)</p>
                <p><bold>Travel, Accommodations, Expenses:</bold> PharmaMar</p>
              </sec>
              <sec id="s27">
                <title>Howard Burris</title>
                <p><bold>Employment:</bold> HCA Healthcare/Sarah Cannon</p>
                <p><bold>Leadership:</bold> HCA Healthcare/Sarah Cannon</p>
                <p><bold>Stock and Other Ownership Interests:</bold> HCA Healthcare/Sarah Cannon</p>
                <p><bold>Consulting or Advisory Role:</bold> AstraZeneca (Inst), FORMA Therapeutics (Inst), Celgene (Inst), Incyte (Inst)</p>
                <p><bold>Research Funding:</bold> Roche/Genentech (Inst), Bristol-Myers Squibb (Inst), Incyte (Inst), AstraZeneca (Inst), MedImmune (Inst), Macrogenics (Inst), Novartis (Inst), Boehringer Ingelheim (Inst), Lilly (Inst), Seattle Genetics (Inst), Merck (Inst), Agios (Inst), Jounce Therapeutics (Inst), Moderna Therapeutics (Inst), CytomX Therapeutics (Inst), GlaxoSmithKline (Inst), Verastem (Inst), Tesaro (Inst), Millennium (Inst), BioMed Valley Discoveries (Inst), TG Therapeutics (Inst), Vertex (Inst), eFFECTOR Therapeutics (Inst), Janssen (Inst), Gilead Sciences (Inst), BioAtla (Inst), CicloMed (Inst), Harpoon therapeutics (Inst), Arch (Inst), Arvinas (Inst), Revolution Medicines (Inst), Array BioPharma (Inst), Bayer (Inst), BIND Therapeutics (Inst), Kymab (Inst), miRNA Therapeutics (Inst), Pfizer (Inst)</p>
                <p><bold>Expert Testimony:</bold> Novartis (Inst)</p>
                <p><bold>Uncompensated Relationships:</bold> Daiichi Sankyo (Inst), Pfizer (Inst)</p>
                <p>
                  <bold>Open Payments Link:</bold>
                  <ext-link ext-link-type="uri" xlink:href="https://openpaymentsdata.cms.gov/physician/201030/summary">https://openpaymentsdata.cms.gov/physician/201030/summary</ext-link>
                </p>
              </sec>
              <sec id="s28">
                <title>Filip Janku</title>
                <p><bold>Stock and Other Ownership Interests:</bold> Trovagene</p>
                <p><bold>Consulting or Advisory Role:</bold> Deciphera, Trovagene, Novartis, Sequenom, Foundation Medicine, Guardant Health, Synlogic, Valeant/Dendreon, IFM Therapeutics, Sotio, PureTech, Jazz Pharmaceuticals, Immunomet, IDEAYA Biosciences</p>
                <p><bold>Research Funding:</bold> Novartis (Inst), BioMed Valley Discoveries (Inst), Roche (Inst), Agios (Inst), Astellas Pharma (Inst), Deciphera (Inst), Plexxikon (Inst), Piqur (Inst), Fujifilm (Inst), Symphogen (Inst), Bristol-Myers Squibb (Inst), Asana Biosciences (Inst), Astex Pharmaceuticals (Inst), Genentech (Inst), Bristol-Myers Squibb (Inst), Proximagen (Inst)</p>
                <p><bold>Other Relationship:</bold> Bio-Rad</p>
              </sec>
              <sec id="s29">
                <title>Robert J. Young</title>
                <p><bold>Stock and Other Ownership Interests:</bold> Alexion, Agios, Biogen, Celgene, Gilead Sciences, Karyopharm Therapeutics, Spark Therapeutics, Regeneron, Stemline Therapeutics, Vertex, Merck, Amgen</p>
                <p><bold>Consulting or Advisory Role:</bold> Agios, Puma Biotechnology, NordicNeuroLab, ICON Clinical Research</p>
                <p><bold>Research Funding:</bold> Agios (Ins)</p>
              </sec>
              <sec id="s30">
                <title>Raymond Huang</title>
                <p><bold>Consulting or Advisory Role:</bold> Agios</p>
                <p><bold>Research Funding:</bold> Agios</p>
              </sec>
              <sec id="s31">
                <title>Liewen Jiang</title>
                <p><bold>Employment:</bold> Agios</p>
                <p><bold>Stock and Other Ownership Interests:</bold> Agios</p>
              </sec>
              <sec id="s32">
                <title>Sung Choe</title>
                <p><bold>Employment:</bold> Agios</p>
                <p><bold>Stock and Other Ownership Interests:</bold> Agios</p>
                <p><bold>Patents, Royalties, Other Intellectual Property:</bold> Patents derived from my work at Agios</p>
                <p><bold>Travel, Accommodations, Expenses:</bold> Agios</p>
              </sec>
              <sec id="s33">
                <title>Bin Fan</title>
                <p><bold>Employment:</bold> Agios</p>
                <p><bold>Stock and Other Ownership Interests:</bold> Agios</p>
                <p><bold>Travel, Accommodations, Expenses:</bold> Agios</p>
              </sec>
              <sec id="s34">
                <title>Katherine Yen</title>
                <p><bold>Employment:</bold> Agios Pharmaceuticals</p>
                <p><bold>Leadership:</bold> Auron Therapeutics</p>
                <p><bold>Stock and Other Ownership Interests:</bold> Agios Therapeutics, Auron Therapeutics</p>
                <p><bold>Consulting or Advisory Role:</bold> Agios Therapeutics</p>
                <p><bold>Research Funding:</bold> Auron Therapeutics, Auron Therapeutics</p>
                <p><bold>Patents, Royalties, Other Intellectual Property:</bold> Patents around IDH mutant inhibitors and methods of treatment</p>
                <p><bold>Travel, Accommodations, Expenses:</bold> Agios Therapeutics, Auron Therapeutics</p>
              </sec>
              <sec id="s35">
                <title>Min Lu</title>
                <p><bold>Employment:</bold> Agios</p>
                <p><bold>Stock and Other Ownership Interests:</bold> Agios</p>
              </sec>
              <sec id="s36">
                <title>Chris Bowden</title>
                <p><bold>Employment:</bold> Agios</p>
                <p><bold>Leadership:</bold> Agios, Miragen, Ziopharm</p>
                <p><bold>Stock and Other Ownership Interests:</bold> Agios</p>
              </sec>
              <sec id="s37">
                <title>Lori Steelman</title>
                <p><bold>Employment:</bold> Agios</p>
                <p><bold>Stock and Other Ownership Interests:</bold> Infinity Pharmaceuticals</p>
              </sec>
              <sec id="s38">
                <title>Shuchi S. Pandya</title>
                <p><bold>Employment:</bold> Agios Pharmaceuticals</p>
                <p><bold>Stock and Other Ownership Interests:</bold> Agios</p>
                <p><bold>Research Funding:</bold> Agios</p>
                <p><bold>Travel, Accommodations, Expenses:</bold> Agios</p>
              </sec>
              <sec id="s39">
                <title>Timothy F. Cloughesy</title>
                <p><bold>Stock and Other Ownership Interests:</bold> Notable Labs, Katmai Pharmaceuticals</p>
                <p><bold>Consulting or Advisory Role:</bold> Roche/Genentech, Celgene, Tocagen, VBL Therapeutics, NewGen Therapeutics, Novartis, Agios, Cortice, Novocure, AbbVie, Oxigene, Wellcome Trust, Pfizer, Notable Labs, Bristol-Myers Squibb, Merck, Insys Therapeutics, Human Longevity, Sunovion, Boston Biomedical, Novogen, Alexion Pharmaceuticals, GW Pharmaceuticals, Lilly, Genocea Biosciences, Puma Biotechnology, Deciphera, Boehringer Ingelheim, KIYATEC, VBI Vaccines, Bayer, DelMar Pharmaceuticals, QED, Amgen, Pascal Bio, Karyopharm Therapeutics</p>
                <p><bold>Patents, Royalties, Other Intellectual Property:</bold> U.S. Provisional application No. 62/819,322: Compositions and methods for treating cancer; Filing date: March 15, 2019; Inventor(s): David A. Nathanson et al. FH Reference No. UCH-17760 (32246-17760)Your Reference No. [UCLA 2019-630-1] US</p>
                <p><bold>Other Relationship:</bold> Global Coalition for Adaptive Research 501(c)(3)</p>
              </sec>
              <sec id="s40">
                <title>Patrick Y. Wen</title>
                <p><bold>Consulting or Advisory Role:</bold> Agios, AstraZeneca, Vascular Biogenics, Immunomic Therapeutics, Kayatec, Puma Biotechnology, Taiho Pharmaceutical, Deciphera, VBI Vaccines, Tocagen, Bayer, Blue Earth Diagnostics, Karyopharm, Deciphera, Voyager, Taiho Pharmaceutical, QED, Imvax, Elevate Bio, Integral Health</p>
                <p><bold>Speakers' Bureau:</bold> Merck, Prime Oncology</p>
                <p><bold>Research Funding:</bold> Agios (Inst), AbbVie (Inst), AstraZeneca (Inst), Merck (Inst), Novartis (Inst), Oncoceutics (Inst), Lilly (Inst), AstraZeneca (Inst), Beigene (Inst), Kazia (Inst), MediciNova (Inst), Vacular Biogenics (Inst), VBI Vaccines (Inst), Puma (Inst), Celgene (Inst), Bayer (Inst)</p>
                <p>No other potential conflicts of interest were reported.</p>
              </sec>
            </sec>
            <ref-list>
              <title>REFERENCES</title>
              <ref id="B1">
                <label>1.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Mandonnet</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Delattre</surname>
                      <given-names>JY</given-names>
                    </name>
                    <name>
                      <surname>Tanguy</surname>
                      <given-names>ML</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Continuous growth of mean tumor diameter in a subset of grade II gliomas</article-title>
                  <source>Ann Neurol</source>
                  <volume>53</volume>
                  <fpage>524</fpage>
                  <lpage>528</lpage>
                  <year>2003</year>
                  <pub-id pub-id-type="pmid">12666121</pub-id>
                </mixed-citation>
              </ref>
              <ref id="B2">
                <label>2.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>van den Bent</surname>
                      <given-names>MJ</given-names>
                    </name>
                    <name>
                      <surname>Smits</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Kros</surname>
                      <given-names>JM</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Diffuse infiltrating oligodendroglioma and astrocytoma</article-title>
                  <source>J Clin Oncol</source>
                  <volume>35</volume>
                  <fpage>2394</fpage>
                  <lpage>2401</lpage>
                  <year>2017</year>
                  <pub-id pub-id-type="pmid">28640702</pub-id>
                </mixed-citation>
              </ref>
              <ref id="B3">
                <label>3.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Weller</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>van den Bent</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Tonn</surname>
                      <given-names>JC</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas</article-title>
                  <source>Lancet Oncol</source>
                  <volume>18</volume>
                  <fpage>e315</fpage>
                  <lpage>e329</lpage>
                  <year>2017</year>
                  <pub-id pub-id-type="pmid">28483413</pub-id>
                </mixed-citation>
              </ref>
              <ref id="B4">
                <label>4.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Buckner</surname>
                      <given-names>JC</given-names>
                    </name>
                    <name>
                      <surname>Shaw</surname>
                      <given-names>EG</given-names>
                    </name>
                    <name>
                      <surname>Pugh</surname>
                      <given-names>SL</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Radiation plus procarbazine, CCNU, and vincristine in low-grade glioma</article-title>
                  <source>N Engl J Med</source>
                  <volume>374</volume>
                  <fpage>1344</fpage>
                  <lpage>1355</lpage>
                  <year>2016</year>
                  <pub-id pub-id-type="pmid">27050206</pub-id>
                </mixed-citation>
              </ref>
              <ref id="B5">
                <label>5.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Jonsson</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Lin</surname>
                      <given-names>AL</given-names>
                    </name>
                    <name>
                      <surname>Young</surname>
                      <given-names>RJ</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Genomic correlates of disease progression and treatment response in prospectively characterized gliomas</article-title>
                  <source>Clin Cancer Res</source>
                  <volume>25</volume>
                  <fpage>5537</fpage>
                  <lpage>5547</lpage>
                  <year>2019</year>
                  <pub-id pub-id-type="pmid">31263031</pub-id>
                </mixed-citation>
              </ref>
              <ref id="B6">
                <label>6.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Cairncross</surname>
                      <given-names>JG</given-names>
                    </name>
                    <name>
                      <surname>Pexman</surname>
                      <given-names>JH</given-names>
                    </name>
                    <name>
                      <surname>Rathbone</surname>
                      <given-names>MP</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Postoperative contrast enhancement in patients with brain tumor</article-title>
                  <source>Ann Neurol</source>
                  <volume>17</volume>
                  <fpage>570</fpage>
                  <lpage>572</lpage>
                  <year>1985</year>
                  <pub-id pub-id-type="pmid">4026227</pub-id>
                </mixed-citation>
              </ref>
              <ref id="B7">
                <label>7.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Pallud</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Taillandier</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Capelle</surname>
                      <given-names>L</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Quantitative morphological magnetic resonance imaging follow-up of low-grade glioma: A plea for systematic measurement of growth rates</article-title>
                  <source>Neurosurgery</source>
                  <volume>71</volume>
                  <fpage>729</fpage>
                  <lpage>739, discussion 739-740</lpage>
                  <year>2012</year>
                  <pub-id pub-id-type="pmid">22668885</pub-id>
                </mixed-citation>
              </ref>
              <ref id="B8">
                <label>8.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Yan</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Parsons</surname>
                      <given-names>DW</given-names>
                    </name>
                    <name>
                      <surname>Jin</surname>
                      <given-names>G</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title><italic>IDH1</italic> and <italic>IDH2</italic> mutations in gliomas</article-title>
                  <source>N Engl J Med</source>
                  <volume>360</volume>
                  <fpage>765</fpage>
                  <lpage>773</lpage>
                  <year>2009</year>
                  <pub-id pub-id-type="pmid">19228619</pub-id>
                </mixed-citation>
              </ref>
              <ref id="B9">
                <label>9.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Parsons</surname>
                      <given-names>DW</given-names>
                    </name>
                    <name>
                      <surname>Jones</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Zhang</surname>
                      <given-names>X</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>An integrated genomic analysis of human glioblastoma multiforme</article-title>
                  <source>Science</source>
                  <volume>321</volume>
                  <fpage>1807</fpage>
                  <lpage>1812</lpage>
                  <year>2008</year>
                  <pub-id pub-id-type="pmid">18772396</pub-id>
                </mixed-citation>
              </ref>
              <ref id="B10">
                <label>10.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Watanabe</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Nobusawa</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Kleihues</surname>
                      <given-names>P</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title><italic>IDH1</italic> mutations are early events in the development of astrocytomas and oligodendrogliomas</article-title>
                  <source>Am J Pathol</source>
                  <volume>174</volume>
                  <fpage>1149</fpage>
                  <lpage>1153</lpage>
                  <year>2009</year>
                  <pub-id pub-id-type="pmid">19246647</pub-id>
                </mixed-citation>
              </ref>
              <ref id="B11">
                <label>11.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>van den Bent</surname>
                      <given-names>MJ</given-names>
                    </name>
                    <name>
                      <surname>Dubbink</surname>
                      <given-names>HJ</given-names>
                    </name>
                    <name>
                      <surname>Marie</surname>
                      <given-names>Y</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: A report of the European Organization for Research and Treatment of Cancer Brain Tumor Group</article-title>
                  <source>Clin Cancer Res</source>
                  <volume>16</volume>
                  <fpage>1597</fpage>
                  <lpage>1604</lpage>
                  <year>2010</year>
                  <pub-id pub-id-type="pmid">20160062</pub-id>
                </mixed-citation>
              </ref>
              <ref id="B12">
                <label>12.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Turcan</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Rohle</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Goenka</surname>
                      <given-names>A</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype</article-title>
                  <source>Nature</source>
                  <volume>483</volume>
                  <fpage>479</fpage>
                  <lpage>483</lpage>
                  <year>2012</year>
                  <pub-id pub-id-type="pmid">22343889</pub-id>
                </mixed-citation>
              </ref>
              <ref id="B13">
                <label>13.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Sanson</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Marie</surname>
                      <given-names>Y</given-names>
                    </name>
                    <name>
                      <surname>Paris</surname>
                      <given-names>S</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas</article-title>
                  <source>J Clin Oncol</source>
                  <volume>27</volume>
                  <fpage>4150</fpage>
                  <lpage>4154</lpage>
                  <year>2009</year>
                  <pub-id pub-id-type="pmid">19636000</pub-id>
                </mixed-citation>
              </ref>
              <ref id="B14">
                <label>14.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Noushmehr</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Weisenberger</surname>
                      <given-names>DJ</given-names>
                    </name>
                    <name>
                      <surname>Diefes</surname>
                      <given-names>K</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma</article-title>
                  <source>Cancer Cell</source>
                  <volume>17</volume>
                  <fpage>510</fpage>
                  <lpage>522</lpage>
                  <year>2010</year>
                  <pub-id pub-id-type="pmid">20399149</pub-id>
                </mixed-citation>
              </ref>
              <ref id="B15">
                <label>15.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Brat</surname>
                      <given-names>DJ</given-names>
                    </name>
                    <name>
                      <surname>Verhaak</surname>
                      <given-names>RG</given-names>
                    </name>
                    <name>
                      <surname>Aldape</surname>
                      <given-names>KD</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Comprehensive, integrative genomic analysis of diffuse lower grade gliomas</article-title>
                  <source>N Engl J Med</source>
                  <volume>372</volume>
                  <fpage>2481</fpage>
                  <lpage>2498</lpage>
                  <year>2015</year>
                  <pub-id pub-id-type="pmid">26061751</pub-id>
                </mixed-citation>
              </ref>
              <ref id="B16">
                <label>16.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Dang</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>White</surname>
                      <given-names>DW</given-names>
                    </name>
                    <name>
                      <surname>Gross</surname>
                      <given-names>S</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Cancer-associated IDH1 mutations produce 2-hydroxyglutarate</article-title>
                  <source>Nature</source>
                  <volume>462</volume>
                  <fpage>739</fpage>
                  <lpage>744</lpage>
                  <year>2009</year>
                  <pub-id pub-id-type="pmid">19935646</pub-id>
                </mixed-citation>
              </ref>
              <ref id="B17">
                <label>17.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Ward</surname>
                      <given-names>PS</given-names>
                    </name>
                    <name>
                      <surname>Patel</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Wise</surname>
                      <given-names>DR</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate</article-title>
                  <source>Cancer Cell</source>
                  <volume>17</volume>
                  <fpage>225</fpage>
                  <lpage>234</lpage>
                  <year>2010</year>
                  <pub-id pub-id-type="pmid">20171147</pub-id>
                </mixed-citation>
              </ref>
              <ref id="B18">
                <label>18.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Chowdhury</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Yeoh</surname>
                      <given-names>KK</given-names>
                    </name>
                    <name>
                      <surname>Tian</surname>
                      <given-names>YM</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases</article-title>
                  <source>EMBO Rep</source>
                  <volume>12</volume>
                  <fpage>463</fpage>
                  <lpage>469</lpage>
                  <year>2011</year>
                  <pub-id pub-id-type="pmid">21460794</pub-id>
                </mixed-citation>
              </ref>
              <ref id="B19">
                <label>19.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Xu</surname>
                      <given-names>W</given-names>
                    </name>
                    <name>
                      <surname>Yang</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Liu</surname>
                      <given-names>Y</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases</article-title>
                  <source>Cancer Cell</source>
                  <volume>19</volume>
                  <fpage>17</fpage>
                  <lpage>30</lpage>
                  <year>2011</year>
                  <pub-id pub-id-type="pmid">21251613</pub-id>
                </mixed-citation>
              </ref>
              <ref id="B20">
                <label>20.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Losman</surname>
                      <given-names>JA</given-names>
                    </name>
                    <name>
                      <surname>Looper</surname>
                      <given-names>RE</given-names>
                    </name>
                    <name>
                      <surname>Koivunen</surname>
                      <given-names>P</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>(R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible</article-title>
                  <source>Science</source>
                  <volume>339</volume>
                  <fpage>1621</fpage>
                  <lpage>1625</lpage>
                  <year>2013</year>
                  <pub-id pub-id-type="pmid">23393090</pub-id>
                </mixed-citation>
              </ref>
              <ref id="B21">
                <label>21.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Wang</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Travins</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>DeLaBarre</surname>
                      <given-names>B</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation</article-title>
                  <source>Science</source>
                  <volume>340</volume>
                  <fpage>622</fpage>
                  <lpage>626</lpage>
                  <year>2013</year>
                  <pub-id pub-id-type="pmid">23558173</pub-id>
                </mixed-citation>
              </ref>
              <ref id="B22">
                <label>22.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Rohle</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Popovici-Muller</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Palaskas</surname>
                      <given-names>N</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells</article-title>
                  <source>Science</source>
                  <volume>340</volume>
                  <fpage>626</fpage>
                  <lpage>630</lpage>
                  <year>2013</year>
                  <pub-id pub-id-type="pmid">23558169</pub-id>
                </mixed-citation>
              </ref>
              <ref id="B23">
                <label>23.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Kosmider</surname>
                      <given-names>O</given-names>
                    </name>
                    <name>
                      <surname>Gelsi-Boyer</surname>
                      <given-names>V</given-names>
                    </name>
                    <name>
                      <surname>Slama</surname>
                      <given-names>L</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms</article-title>
                  <source>Leukemia</source>
                  <volume>24</volume>
                  <fpage>1094</fpage>
                  <lpage>1096</lpage>
                  <year>2010</year>
                  <pub-id pub-id-type="pmid">20376084</pub-id>
                </mixed-citation>
              </ref>
              <ref id="B24">
                <label>24.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Mardis</surname>
                      <given-names>ER</given-names>
                    </name>
                    <name>
                      <surname>Ding</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Dooling</surname>
                      <given-names>DJ</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Recurring mutations found by sequencing an acute myeloid leukemia genome</article-title>
                  <source>N Engl J Med</source>
                  <volume>361</volume>
                  <fpage>1058</fpage>
                  <lpage>1066</lpage>
                  <year>2009</year>
                  <pub-id pub-id-type="pmid">19657110</pub-id>
                </mixed-citation>
              </ref>
              <ref id="B25">
                <label>25.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Stein</surname>
                      <given-names>EM</given-names>
                    </name>
                    <name>
                      <surname>DiNardo</surname>
                      <given-names>CD</given-names>
                    </name>
                    <name>
                      <surname>Pollyea</surname>
                      <given-names>DA</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Enasidenib in mutant <italic>IDH2</italic> relapsed or refractory acute myeloid leukemia</article-title>
                  <source>Blood</source>
                  <volume>130</volume>
                  <fpage>722</fpage>
                  <lpage>731</lpage>
                  <year>2017</year>
                  <pub-id pub-id-type="pmid">28588020</pub-id>
                </mixed-citation>
              </ref>
              <ref id="B26">
                <label>26.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>DiNardo</surname>
                      <given-names>CD</given-names>
                    </name>
                    <name>
                      <surname>Stein</surname>
                      <given-names>EM</given-names>
                    </name>
                    <name>
                      <surname>de Botton</surname>
                      <given-names>S</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Durable remissions with ivosidenib in <italic>IDH1</italic>-mutated relapsed or refractory AML</article-title>
                  <source>N Engl J Med</source>
                  <volume>378</volume>
                  <fpage>2386</fpage>
                  <lpage>2398</lpage>
                  <year>2018</year>
                  <pub-id pub-id-type="pmid">29860938</pub-id>
                </mixed-citation>
              </ref>
              <ref id="B27">
                <label>27.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Lowery</surname>
                      <given-names>MA</given-names>
                    </name>
                    <name>
                      <surname>Burris</surname>
                      <given-names>HA</given-names>
                      <suffix>III</suffix>
                    </name>
                    <name>
                      <surname>Janku</surname>
                      <given-names>F</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: A phase 1 study</article-title>
                  <source>Lancet Gastroenterol Hepatol</source>
                  <volume>4</volume>
                  <fpage>711</fpage>
                  <lpage>720</lpage>
                  <year>2019</year>
                  <pub-id pub-id-type="pmid">31300360</pub-id>
                </mixed-citation>
              </ref>
              <ref id="B28">
                <label>28.</label>
                <mixed-citation publication-type="journal">
                  <comment>Tap WD, Villalobos VM, Cote GM, et al: Phase 1 study of the mutant IDH1 inhibitor ivosidenib: Safety and clinical activity in patients with advanced chondrosarcoma. J Clin Oncol 38:1693-1701, 2020</comment>
                </mixed-citation>
              </ref>
              <ref id="B29">
                <label>29.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Fan</surname>
                      <given-names>B</given-names>
                    </name>
                    <name>
                      <surname>Mellinghoff</surname>
                      <given-names>IK</given-names>
                    </name>
                    <name>
                      <surname>Wen</surname>
                      <given-names>PY</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Clinical pharmacokinetics and pharmacodynamics of ivosidenib, an oral, targeted inhibitor of mutant IDH1, in patients with advanced solid tumors</article-title>
                  <source>Invest New Drugs</source>
                  <volume>38</volume>
                  <fpage>433</fpage>
                  <lpage>444</lpage>
                  <year>2020</year>
                  <pub-id pub-id-type="pmid">31028664</pub-id>
                </mixed-citation>
              </ref>
              <ref id="B30">
                <label>30.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Louis</surname>
                      <given-names>DN</given-names>
                    </name>
                    <name>
                      <surname>Perry</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Reifenberger</surname>
                      <given-names>G</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>The 2016 World Health Organization classification of Tumors of the Central Nervous System: A summary</article-title>
                  <source>Acta Neuropathol</source>
                  <volume>131</volume>
                  <fpage>803</fpage>
                  <lpage>820</lpage>
                  <year>2016</year>
                  <pub-id pub-id-type="pmid">27157931</pub-id>
                </mixed-citation>
              </ref>
              <ref id="B31">
                <label>31.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Louis</surname>
                      <given-names>DN</given-names>
                    </name>
                    <name>
                      <surname>Ohgaki</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Wiestler</surname>
                      <given-names>OD</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>The 2007 WHO classification of tumours of the central nervous system</article-title>
                  <source>Acta Neuropathol</source>
                  <volume>114</volume>
                  <fpage>97</fpage>
                  <lpage>109</lpage>
                  <year>2007</year>
                  <pub-id pub-id-type="pmid">17618441</pub-id>
                </mixed-citation>
              </ref>
              <ref id="B32">
                <label>32.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Wen</surname>
                      <given-names>PY</given-names>
                    </name>
                    <name>
                      <surname>Macdonald</surname>
                      <given-names>DR</given-names>
                    </name>
                    <name>
                      <surname>Reardon</surname>
                      <given-names>DA</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Updated response assessment criteria for high-grade gliomas: Response assessment in neuro-oncology working group</article-title>
                  <source>J Clin Oncol</source>
                  <volume>28</volume>
                  <fpage>1963</fpage>
                  <lpage>1972</lpage>
                  <year>2010</year>
                  <pub-id pub-id-type="pmid">20231676</pub-id>
                </mixed-citation>
              </ref>
              <ref id="B33">
                <label>33.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>van den Bent</surname>
                      <given-names>MJ</given-names>
                    </name>
                    <name>
                      <surname>Wefel</surname>
                      <given-names>JS</given-names>
                    </name>
                    <name>
                      <surname>Schiff</surname>
                      <given-names>D</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Response assessment in neuro-oncology (a report of the RANO group): Assessment of outcome in trials of diffuse low-grade gliomas</article-title>
                  <source>Lancet Oncol</source>
                  <volume>12</volume>
                  <fpage>583</fpage>
                  <lpage>593</lpage>
                  <year>2011</year>
                  <pub-id pub-id-type="pmid">21474379</pub-id>
                </mixed-citation>
              </ref>
              <ref id="B34">
                <label>34.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Ellingson</surname>
                      <given-names>BM</given-names>
                    </name>
                    <name>
                      <surname>Bendszus</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Boxerman</surname>
                      <given-names>J</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Consensus recommendations for a standardized brain tumor imaging protocol in clinical trials</article-title>
                  <source>Neuro-oncol</source>
                  <volume>17</volume>
                  <fpage>1188</fpage>
                  <lpage>1198</lpage>
                  <year>2015</year>
                  <pub-id pub-id-type="pmid">26250565</pub-id>
                </mixed-citation>
              </ref>
              <ref id="B35">
                <label>35.</label>
                <mixed-citation publication-type="book">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Fitzmaurice</surname>
                      <given-names>GM</given-names>
                    </name>
                    <name>
                      <surname>Laird</surname>
                      <given-names>NM</given-names>
                    </name>
                    <name>
                      <surname>Ware</surname>
                      <given-names>JH</given-names>
                    </name>
                  </person-group>
                  <source>Applied longitudinal analysis</source>
                  <edition>ed 2</edition>
                  <publisher-loc>Hoboken, NJ</publisher-loc>
                  <publisher-name>John Wiley &amp; Sons</publisher-name>
                  <year>2011</year>
                </mixed-citation>
              </ref>
              <ref id="B36">
                <label>36.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Frampton</surname>
                      <given-names>GM</given-names>
                    </name>
                    <name>
                      <surname>Fichtenholtz</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Otto</surname>
                      <given-names>GA</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing</article-title>
                  <source>Nat Biotechnol</source>
                  <volume>31</volume>
                  <fpage>1023</fpage>
                  <lpage>1031</lpage>
                  <year>2013</year>
                  <pub-id pub-id-type="pmid">24142049</pub-id>
                </mixed-citation>
              </ref>
              <ref id="B37">
                <label>37.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Reuter</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Gerstner</surname>
                      <given-names>ER</given-names>
                    </name>
                    <name>
                      <surname>Rapalino</surname>
                      <given-names>O</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Impact of MRI head placement on glioma response assessment</article-title>
                  <source>J Neurooncol</source>
                  <volume>118</volume>
                  <fpage>123</fpage>
                  <lpage>129</lpage>
                  <year>2014</year>
                  <pub-id pub-id-type="pmid">24566765</pub-id>
                </mixed-citation>
              </ref>
              <ref id="B38">
                <label>38.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Dubbink</surname>
                      <given-names>HJ</given-names>
                    </name>
                    <name>
                      <surname>Taal</surname>
                      <given-names>W</given-names>
                    </name>
                    <name>
                      <surname>van Marion</surname>
                      <given-names>R</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title><italic>IDH1</italic> mutations in low-grade astrocytomas predict survival but not response to temozolomide</article-title>
                  <source>Neurology</source>
                  <volume>73</volume>
                  <fpage>1792</fpage>
                  <lpage>1795</lpage>
                  <year>2009</year>
                  <pub-id pub-id-type="pmid">19933982</pub-id>
                </mixed-citation>
              </ref>
              <ref id="B39">
                <label>39.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Nahed</surname>
                      <given-names>BV</given-names>
                    </name>
                    <name>
                      <surname>Redjal</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Brat</surname>
                      <given-names>DJ</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Management of patients with recurrence of diffuse low grade glioma: A systematic review and evidence-based clinical practice guideline</article-title>
                  <source>J Neurooncol</source>
                  <volume>125</volume>
                  <fpage>609</fpage>
                  <lpage>630</lpage>
                  <year>2015</year>
                  <pub-id pub-id-type="pmid">26530264</pub-id>
                </mixed-citation>
              </ref>
              <ref id="B40">
                <label>40.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Rees</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Watt</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Jäger</surname>
                      <given-names>HR</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Volumes and growth rates of untreated adult low-grade gliomas indicate risk of early malignant transformation</article-title>
                  <source>Eur J Radiol</source>
                  <volume>72</volume>
                  <fpage>54</fpage>
                  <lpage>64</lpage>
                  <year>2009</year>
                  <pub-id pub-id-type="pmid">18632238</pub-id>
                </mixed-citation>
              </ref>
              <ref id="B41">
                <label>41.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Freyschlag</surname>
                      <given-names>CF</given-names>
                    </name>
                    <name>
                      <surname>Krieg</surname>
                      <given-names>SM</given-names>
                    </name>
                    <name>
                      <surname>Kerschbaumer</surname>
                      <given-names>J</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Imaging practice in low-grade gliomas among European specialized centers and proposal for a minimum core of imaging</article-title>
                  <source>J Neurooncol</source>
                  <volume>139</volume>
                  <fpage>699</fpage>
                  <lpage>711</lpage>
                  <year>2018</year>
                  <pub-id pub-id-type="pmid">29992433</pub-id>
                </mixed-citation>
              </ref>
              <ref id="B42">
                <label>42.</label>
                <mixed-citation publication-type="other">
                  <comment>Mellinghoff IK, Cloughesy TF, Wen PY, et al: A phase 1, open-label, perioperative study of AG-120 and AG-881 in recurrent IDH1 mutant, low-grade glioma: Results from cohort 1. J Clin Oncol 37(15_suppl abstr):2003, 2019</comment>
                </mixed-citation>
              </ref>
              <ref id="B43">
                <label>43.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Druker</surname>
                      <given-names>BJ</given-names>
                    </name>
                    <name>
                      <surname>Talpaz</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Resta</surname>
                      <given-names>DJ</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia</article-title>
                  <source>N Engl J Med</source>
                  <volume>344</volume>
                  <fpage>1031</fpage>
                  <lpage>1037</lpage>
                  <year>2001</year>
                  <pub-id pub-id-type="pmid">11287972</pub-id>
                </mixed-citation>
              </ref>
              <ref id="B44">
                <label>44.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Druker</surname>
                      <given-names>BJ</given-names>
                    </name>
                    <name>
                      <surname>Sawyers</surname>
                      <given-names>CL</given-names>
                    </name>
                    <name>
                      <surname>Kantarjian</surname>
                      <given-names>H</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome</article-title>
                  <source>N Engl J Med</source>
                  <volume>344</volume>
                  <fpage>1038</fpage>
                  <lpage>1042</lpage>
                  <year>2001</year>
                  <pub-id pub-id-type="pmid">11287973</pub-id>
                </mixed-citation>
              </ref>
              <ref id="B45">
                <label>45.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Shirahata</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Ono</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Stichel</surname>
                      <given-names>D</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Novel, improved grading system(s) for IDH-mutant astrocytic gliomas</article-title>
                  <source>Acta Neuropathol</source>
                  <volume>136</volume>
                  <fpage>153</fpage>
                  <lpage>166</lpage>
                  <year>2018</year>
                  <pub-id pub-id-type="pmid">29687258</pub-id>
                </mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
